United BioSource Selects Oracle Cloud Safety Technology for its Safety Programs
United BioSource (UBC) has migrated its safety functions from on-premises to Oracle Argus Cloud Service, a safety case management solution.
Running on the security and performance of Oracle Cloud Infrastructure, Oracle Argus Cloud Service will provide UBC with safety case processing for its clinical trials as well as post-marketing programs. With it, UBC can optimize its workflow by automating routine steps, reducing manual work, and cutting processing times. It also enables UBC to address its global compliance goals with aggregated and expedited reporting.
Oracle Argus Cloud Service can provide UBC with safety case management features and benefits including:
- Capabilities to help address compliance with global regulations and standards
- Lower cost and complexity through SaaS deployment
- Efficient case processing via automation
- Analytics and reports
- Lower total cost of ownership
Reference
United BioSource, LLC Selects Oracle Cloud Safety Technology for its Safety Programs. (2023, August 1). Cision PR Newswire.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
